



BioLineRx to Present at the Oppenheimer 14th Annual Israeli Conference on May 12th

May 9, 2013

JERUSALEM--(BUSINESS WIRE)--May. 9, 2013-- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that its Chief Executive Officer, Kinneret Savitsky, Ph.D., and its Chief Financial and Operating Officer, Philip Serlin, will present at the Oppenheimer 14th Annual Israeli Conference on Sunday, May 12, 2013, at 12:00 p.m. Israeli local time. The conference is being held at the David Intercontinental Hotel in Tel Aviv, Israel.

About BioLineRx

BioLineRx is a publicly-traded biopharmaceutical development company. BioLineRx is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. BioLineRx's current portfolio consists of seven clinical stage candidates: BL-1040, for prevention of pathological cardiac remodeling following a myocardial infarction, which has been out-licensed to Ikaria Inc., is currently undergoing a pivotal CE-Mark registration trial; BL-5010 for non-surgical removal of skin lesions has completed a Phase 1/2 study; BL-7040 for treating inflammatory bowel disease (IBD) has completed a Phase 2a trial; BL-8040 for treating acute myeloid leukemia (AML) and other hematological cancers will shortly commence a Phase 2 study; BL-1021 for neuropathic pain is in Phase 1 development; BL-8020 for hepatitis C (HCV) has commenced a Phase 1/2 study; and BL-1020 for schizophrenia. In addition, BioLineRx has five products in various pre-clinical development stages for a variety of indications, including central nervous system diseases, infectious diseases, cardiovascular and autoimmune diseases.

BioLineRx's business model is based on acquiring molecules mainly from biotechnological incubators and academic institutions. The Company performs feasibility assessment studies and development through pre-clinical and clinical stages, with partial funding from the Israeli Government's Office of the Chief Scientist (OCS). The final stage includes partnering with medium and large pharmaceutical companies for advanced clinical development (Phase 3) and commercialization. For more information on BioLineRx, please visit www.bioglinerx.com, the content of which does not form a part of this press release.

Source: BioLineRx Ltd.

KCSA Strategic Communications
Garth Russell, 1-212-896-1250
grussell@kcsa.com

or

Todd Fromer, 1-212-896-1250
tfromer@kcsa.com

or

Tsipi Haitovsky, Public Relations
+972-3-6240871
tsipih@netvision.net.il